Avanos Medical Yönetim

Yönetim kriter kontrolleri 3/4

Avanos Medical CEO'su Michael Greiner, Jan2020 tarihinde atandı, in görev süresi 4.83 yıldır. in toplam yıllık tazminatı $ 2.99M olup, şirket hissesi ve opsiyonları dahil olmak üzere 18.7% maaş ve 81.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.13% ine doğrudan sahiptir ve bu hisseler € 993.62K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.8 yıl ve 10.1 yıldır.

Anahtar bilgiler

Michael Greiner

İcra Kurulu Başkanı

US$3.0m

Toplam tazminat

CEO maaş yüzdesi	18.7%
CEO görev süresi	4.8yrs
CEO sahipliği	0.1%
Yönetim ortalama görev süresi	3.8yrs
Yönetim Kurulu ortalama görev süresi	10.1yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Michael Greiner'un ücretlendirmesi Avanos Medical'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	US$22m
Jun 30 2024	n/a	n/a	US$7m
Mar 31 2024	n/a	n/a	-US$2m
Dec 31 2023	US$3m	US$558k	-US$10m
Sep 30 2023	n/a	n/a	-US$11m
Jun 30 2023	n/a	n/a	US$9m
Mar 31 2023	n/a	n/a	US$18m
Dec 31 2022	US$3m	US$514k	US$22m
Sep 30 2022	n/a	n/a	US$23m
Jun 30 2022	n/a	n/a	-US$23m
Mar 31 2022	n/a	n/a	US$10m
Dec 31 2021	US$2m	US$491k	-US$31m
Sep 30 2021	n/a	n/a	-US$52m
Jun 30 2021	n/a	n/a	US$2m
Mar 31 2021	n/a	n/a	-US$38m
Dec 31 2020	US$3m	US$480k	-US$29m

Tazminat ve Piyasa: Michael 'nin toplam tazminatı ($USD 2.99M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.46M ).

Tazminat ve Kazançlar: Michael 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Michael Greiner (51 yo)

4.8yrs

Görev süresi

US$2,986,702

Tazminat

Mr. Michael C. Greiner has been Senior Vice President and Chief Financial Officer of Avanos Medical, Inc. since January 1, 2020 serves as its Chief Transformation Officer since January 10, 2023 and serves...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Michael Greiner	Interim CEO	4.8yrs	US$2.99m	0.13% € 993.6k
Mojirade James	Senior VP	3.3yrs	US$1.90m	0.045% € 342.9k
Kerr Holbrook	Senior VP & Chief Commercial Officer	5.5yrs	US$2.15m	0.20% € 1.5m
John Hurley	Principal Accounting Officer & Controller	2.6yrs	Veri yok	0.0091% € 69.5k
David Crawford	VP of FP&A and Investor Relations and Treasurer	no data	Veri yok	Veri yok
Michelle Scharfenberg	Senior VP and Chief Ethics & Compliance Officer	4.2yrs	Veri yok	Veri yok
Scott Galovan	Vice President of Strategy & Corporate Development	no data	Veri yok	Veri yok
John Cato	Vice President of Human Resources	no data	Veri yok	Veri yok
Lee Burnes	Senior Vice President of Global R&D	no data	Veri yok	Veri yok
Sigfrido Delgado	Senior Vice President of Integrated Supply Chain	less than a year	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: 8HH 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.8 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Patrick O'Leary	Independent Director	10.1yrs	US$292.54k	0.13% € 970.1k
Gary Blackford	Independent Chairman	10.1yrs	US$390.00k	0.14% € 1.1m
Lisa Egbuonu-Davis	Independent Director	1.7yrs	US$245.15k	0.032% € 245.2k
Julie Shimer	Independent Director	10.1yrs	US$289.38k	0.12% € 889.3k
Indrani M. Franchini	Independent Director	less than a year	Veri yok	Veri yok

10.1yrs

Ortalama Görev Süresi

66yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 8HH 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.1 yıldır).

Avanos Medical Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Avanos Medical, Inc. Announces Chief Executive Officer Changes

Avanos Medical, Inc. Appoints Indrani Franchini to its Board of Directors

Avanos Medical, Inc. Appoints Sigfrido (Sig) Delgado as Senior Vice President, Integrated Supply Chain

Senior VP recently sold €140k worth of stock

Avanos Medical, Inc., Annual General Meeting, Apr 25, 2024

Avanos Medical, Inc. Announces Resignation of Arjun R. Sarker as Senior Vice President, Effective May 10, 2023

Recent updates

Investor sentiment deteriorates as stock falls 15%

Avanos Medical, Inc. Launches New CORGRIP SR

Third quarter 2024 earnings released: EPS: US$0.13 (vs US$0.19 loss in 3Q 2023)

Avanos Medical, Inc. Announces Chief Executive Officer Changes

Avanos Medical, Inc. to Report Q3, 2024 Results on Oct 30, 2024

Second quarter 2024 earnings released: EPS: US$0.094 (vs US$0.092 loss in 2Q 2023)

Avanos Medical, Inc. Provides Earnings Guidance for the Full Year 2024

Avanos Medical, Inc. Appoints Indrani Franchini to its Board of Directors

Avanos Medical, Inc. Appoints Sigfrido (Sig) Delgado as Senior Vice President, Integrated Supply Chain

Avanos Medical, Inc. Provides Earnings Guidance for the Year 2024

First quarter 2024 earnings released: EPS: US$0.011 (vs US$0.17 loss in 1Q 2023)

Avanos Medical, Inc. to Report Q1, 2024 Results on May 02, 2024

Senior VP recently sold €140k worth of stock

Avanos Medical, Inc., Annual General Meeting, Apr 25, 2024

Avanos Medical, Inc. Announces Voluntary Recall of Mic Gastric - Jejunal Feeding Tube Kits

Full year 2023 earnings released: US$0.21 loss per share (vs US$1.08 profit in FY 2022)

Avanos Medical, Inc. Provides Earnings Guidance for 2024

Investor sentiment deteriorates as stock falls 20%

Avanos Medical, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Investor sentiment improves as stock rises 20%

Avanos Medical, Inc. Provides Financial Guidance for the Year 2023

New minor risk - Profit margin trend

Avanos Medical, Inc. to Report Q3, 2023 Results on Nov 01, 2023

New minor risk - Earnings quality

Avanos Medical, Inc. Provides Earnings Guidance for the Year 2023

Second quarter 2023 earnings released: US$0.092 loss per share (vs US$0.24 profit in 2Q 2022)

Avanos Medical, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Avanos Medical, Inc.(NYSE:AVNS) dropped from Russell 2000 Dynamic Index

Avanos Medical, Inc. (NYSE:AVNS) entered into a definitive agreement to acquire Diros Technology Inc.

SunMed, LLC entered into a Purchase Agreement to acquire Respiratory Health Business from Avanos Medical, Inc. (NYSE:AVNS) for $110 million.

Investor sentiment deteriorates as stock falls 19%

First quarter 2023 earnings released: US$0.011 loss per share (vs US$0.12 profit in 1Q 2022)

Full year 2022 earnings released: EPS: US$1.08 (vs US$0.11 in FY 2021)

Avanos Medical, Inc. Announces Resignation of Arjun R. Sarker as Senior Vice President, Effective May 10, 2023

Avanos Medical, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Avanos Medical, Inc. Announces Executive Changes

Insufficient new directors

Avanos Medical, Inc. Appoints Sudhakar Varshney as Senior Vice President, Global Supply Chain & Procurement

Third quarter 2022 earnings released: EPS: US$0.34 (vs US$0.73 loss in 3Q 2021)

Avanos Medical, Inc. Affirms Revenue Guidance for the Full-Year 2022

Avanos Medical, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Avanos Medical, Inc. Announces Resignation of Maria Sainz, Member of the Board of Directors, Effective January 1, 2023

Second quarter 2022 earnings released: EPS: US$0.24 (vs US$0.79 in 2Q 2021)

Avanos Medical, Inc. Provides Earnings Outlook for the Full Year 2022

Avanos Medical, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Avanos Medical, Inc. (NYSE:AVNS) announces an Equity Buyback for $25 million worth of its shares.

First quarter 2022 earnings released: EPS: US$0.12 (vs US$0.16 loss in 1Q 2021)

Avanos Medical, Inc. Affirms Earnings Guidance for the Year 2022

Insufficient new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Avanos Medical, Inc. Provides Sales Guidance for the Full Year 2022

Avanos Medical, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Forecast breakeven date pushed back to 2022

Avanos Medical, Inc. (NYSE:AVNS) announces an Equity Buyback for $30 million worth of its shares.

Insufficient new directors

Third quarter 2021 earnings released: US$0.73 loss per share (vs US$0.40 profit in 3Q 2020)

Forecast to breakeven in 2021

Independent Director recently bought €134k worth of stock

Avanos Medical, Inc. Provides Earnings Guidance for the Full Year 2021

Independent Director Heidi Fields has left the company

Second quarter 2021 earnings released: EPS US$0.79 (vs US$0.063 loss in 2Q 2020)

Avanos Medical, Inc. Announces Net Sales Guidance for 2021

Avanos Medical, Inc., Annual General Meeting, Apr 29, 2021

Avanos Medical, Inc. Provides Earnings Guidance for the Year 2021

Avanos Medical, Inc. to Report Q4, 2020 Results on Feb 18, 2021

New 90-day high: €40.60

Avanos Medical, Inc. Announces Appointments

Avanos Medical, Inc. to Report Q3, 2020 Results on Nov 03, 2020

Avanos Medical, Inc. Announces Management Changes